

FORM PTO-1390
(REV. 11-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

2617 USOP

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

10,019094

INTERNATIONAL APPLICATION NO.
PCT/JP00/04036INTERNATIONAL FILING DATE
June 21, 2000PRIORITY DATE CLAIMED
June 22, 1999TITLE OF INVENTION
PRODUCTION METHOD OF IMIDAZOLE DERIVATIVESAPPLICANT(S) FOR DO/EO/US
Jun-ichi KAWAKAMI

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☒ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☒ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 20 below concern document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment.
14. ☐ A SECOND or SUBSEQUENT preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☒ Other items or information:

Copy of first page of published application
 Copies of Forms 101, 210, 301, 304, 308, 332 and 409
 Itemized Return Postcard

Express Mail Label No. EL 916492355 US

Date of Deposit 12/20/01

21. ☒ The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):

Neither international preliminary examination fee (37 CFR 1.482)
nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO
and International Search Report not prepared by the EPO or JPO. \$1040.00

International preliminary examination fee (37 CFR 1.482) not paid to
USPTO but International Search Report prepared by the EPO or JPO \$890.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO
but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$740.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO
but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$710.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO
and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

CALCULATIONS PTO USE ONLY

\$ 890.00

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30
months from the earliest claimed priority date (37 CFR 1.492(e)).

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$
Total claims	42 - 20 =	22	x \$18.00	\$ 396.00
Independent claims	6 - 3 =	3	x \$84.00	\$ 252.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$280.00	\$
TOTAL OF ABOVE CALCULATIONS =				\$ 1538.00
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$
SUBTOTAL =				\$ 1538.00
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$
TOTAL NATIONAL FEE =				\$
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$
TOTAL FEES ENCLOSED =				\$ 1538.00
				Amount to be refunded: \$
				charged: \$

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Mark Chao, PhD, JD
Takeda Pharmaceuticals North America, Inc.
Suite 500, 475 Half Day Road
Lincolnshire, IL 60069 USA
(847)383-3372 fax (847)383-348

SIGNATURE

Mark Chao, PhD, JD

NAME

37,293

REGISTRATION NUMBER

For Customer No. 23,115

10019094-001202
10/019094
531 Rec'd PCT... 20 DEC 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Based Upon	PCT/JP00/04036 filed June 21, 2000	
Application No.:	tba	Art Unit: tba
Filed:	tba	Examiner: tba
1 st Inventor:	KAWAKAMI, J.	Allowed:
For:	Production Method of Imidazole Derivatives	Batch:
Atty. Dkt. No.	2617 US0P	Paper No.:

Preliminary Amendment

BOX PCT
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Please enter the following amendments prior to calculating the appropriate filing fees.

AMENDMENT

In the Specification

Please insert on Page 1 as the first sentence of the application the following:

- - This application is the National Phase filing of International
Patent Application No. PCT/JP00/04036, filed June 21, 2000. - -

In the Claims

On page 34, top of the page please delete [CLAIMS] and insert instead --We Claim:--

Please Substitute the following Claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, and 14 for
the current claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14.

Please add additional claims 18 to 42 inclusive.

Please amend the claims to read as follows:

(1) (AMENDED) A method for producing a compound of the formula:



wherein R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group and ring A is an imidazole ring which is optionally substituted further, or a salt thereof, which method comprises reacting a compound of the formula:




wherein ring A is as defined above, or a salt thereof, and a compound of the formula:



wherein M¹ is an alkali metal atom or a group of the formula:
-Mg-Y¹ where Y¹ is a halogen atom, and R is as defined above, or
a salt thereof, and bringing the resulting product into contact
with an acid.

(2) (AMENDED) A method for producing a compound of the formula:




wherein R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, ring A is an imidazole

ring which is optionally substituted further, and R^1 , R^2 , R^3 , R^4 , R^5 , R^6 and R^7 are each independently a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted hydroxyl group, an optionally substituted thiol group, an optionally substituted amino group, an acyl group or a halogen atom, or a salt thereof, which method comprises reacting a compound of the formula:




wherein each symbol is as defined above, or a salt thereof, and a compound of the formula:



wherein M^2 is an alkali metal atom or a group of the formula: $-Mg-Y^1$ where Y^1 is a halogen atom, and other symbols are as defined above, or a salt thereof.

(3) (AMENDED) A method for producing a compound of the formula:



wherein R is an optionally substituted hydrocarbon group or an

optionally substituted heterocyclic group, ring A is an imidazole ring which is optionally substituted further and R^1 , R^2 , R^3 , R^4 , R^5 , R^6 and R^7 are each independently a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted hydroxyl group, an optionally substituted thiol group, an optionally substituted amino group, an acyl group or a halogen atom, or a salt thereof, which method comprises reacting a compound of the formula:




wherein ring A is as defined above, or a salt thereof, and a compound of the formula:



wherein M^1 is an alkali metal atom or a group of the formula: $-Mg-Y^1$ where Y^1 is a halogen atom, and R is as defined above, or a salt thereof, and bringing the resulting product into contact with an acid to give a compound of the formula:




wherein each symbol is as defined above, or a salt thereof, and then reacting this compound and a compound of the formula:



wherein M^2 is an alkali metal atom or a group of the formula: $-Mg-Y^2$ where Y^2 is a halogen atom, and other symbols are as

defined above, or a salt thereof.


(4) (AMENDED) A method for producing a compound of the formula:



wherein R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, ring A is an imidazole ring which is optionally substituted further and R^1 , R^2 , R^3 , R^4 , R^5 , R^6 and R^7 are each independently a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted hydroxyl group, an optionally substituted thiol group, an optionally substituted amino group, an acyl group or a halogen atom, or a salt thereof, which method comprises reacting a compound of the formula:



wherein ring A is as defined above, or a salt thereof and hydroxylamine or a salt thereof, subjecting the resulting product to dehydration to give a compound of the formula:




wherein ring A is as defined above, or a salt thereof, reacting this compound and a compound of the formula:



[illegible]

wherein each symbol is as defined above, or a salt thereof, and then reacting this compound and a compound of the formula:



wherein M² is an alkali metal atom or a group of the formula: -Mg-Y² where Y² is a halogen atom, and other symbols are as defined above, or a salt thereof.

(5) (AMENDED) The production method described in claim (1), wherein the ring A of the compounds of the formulas (I) and (III) is an imidazole ring wherein the 1- or 3-position is optionally protected.

(6) (AMENDED) The production method described in claim (1), wherein R is an optionally substituted lower alkyl group, an optionally substituted lower alkenyl group, an optionally substituted cycloalkyl group, an optionally substituted phenyl group or an optionally substituted pyridyl group.

(7) (AMENDED) The production method described in claim (1), wherein R is a lower alkenyl group, a cycloalkyl group, a phenyl

group, a pyridyl group, or a lower alkyl group optionally substituted by a halogen atom.

(8) (AMENDED) The production method described in claim (1), wherein R is a C₁₋₆ alkyl group.

(9) (AMENDED) The production method described in claim (1), wherein R is an isopropyl group.

(10) (AMENDED) The production method described in claim (2), wherein M² is sodium, potassium or a group of the formula: -Mg-Y² where Y² is a halogen atom.

(11) (AMENDED) The production method described in claim (1), wherein the reaction product of a compound of the formula (I) or a salt thereof and a compound of the formula (II) or a salt thereof is brought into contact with a sulfuric acid.

(12) (AMENDED) The production method described in claim (1), wherein not less than 3 equivalents of the compound of the formula (II) or a salt thereof is used per one equivalent of the compound of the formula (I) or a salt thereof.

(13) (AMENDED) The production method described in claim (1), wherein the compound of the formula (I) or a salt thereof and the compound of the formula (II) or a salt thereof are reacted in tetrahydrofuran.

(14) (AMENDED) The production method described in claim (1), wherein the compound of the formula (I) or a salt thereof and the compound of the formula (II) or a salt thereof are reacted in not less than 50 equivalents of a solvent relative to one equivalent of the compound of the formula (I) or a salt thereof.

[illegible]

~~[CLAIMS]~~

WE CLAIM:

(1) (AMENDED) A method for producing a compound of the formula:



wherein R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group and ring A is an imidazole ring which is optionally substituted further, or a salt thereof, which method comprises reacting a compound of the formula:




wherein ring A is as defined above, or a salt thereof, and a compound of the formula:



wherein M¹ is an alkali metal atom or a group of the formula:
-Mg-Y¹ [where Y¹ is a halogen atom] and R is as defined
above, or a salt thereof, and bringing the resulting product into
contact with an acid.


(2) (AMENDED) A method for producing a compound of the formula:



wherein R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, ring A is an imidazole ring which is optionally substituted further, and R¹, R², R³, R⁴, R⁵, R⁶ and R⁷ are each independently a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted hydroxyl group, an optionally substituted thiol group, an optionally substituted amino group, an acyl group or a halogen atom, or a salt thereof, which method comprises reacting a compound of the formula:




wherein each symbol is as defined above, or a salt thereof, and a compound of the formula:



wherein M² is an alkali metal atom or a group of the formula:
 $\text{-Mg-Y}^2 \text{ [}\div\text{]}$ where Y¹ is a halogen atom, [÷] and other symbols are as defined above, or a salt thereof.

(3) (AMENDED) A method for producing a compound of the formula:



wherein R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, ring A is an imidazole ring which is optionally substituted further and R^1 , R^2 , R^3 , R^4 , R^5 , R^6 and R^7 are each independently a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted hydroxyl group, an optionally substituted thiol group, an optionally substituted amino group, an acyl group or a halogen atom, or a salt thereof, which method comprises reacting a compound of the formula:



wherein ring A is as defined above, or a salt thereof, and a compound of the formula:




wherein M^1 is an alkali metal atom or a group of the formula: $-Mg-Y^1$ [where Y^1 is a halogen atom] and R is as defined above, or a salt thereof, and bringing the resulting product into contact with an acid to give a compound of the formula:




wherein each symbol is as defined above, or a salt thereof, and

then reacting this compound and a compound of the formula:



wherein M² is an alkali metal atom or a group of the formula:
-Mg-Y² [(-) where Y² is a halogen atom, (+) and other symbols are
as defined above, or a salt thereof.

(4) (AMENDED) A method for producing a compound of the formula:



wherein R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, ring A is an imidazole ring which is optionally substituted further and R¹, R², R³, R⁴, R⁵, R⁶ and R⁷ are each independently a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted hydroxyl group, an optionally substituted thiol group, an optionally substituted amino group, an acyl group or a halogen atom, or a salt thereof, which method comprises reacting a compound of the formula:



wherein ring A is as defined above, or a salt thereof and hydroxylamine or a salt thereof, subjecting the resulting product to dehydration to give a compound of the formula:




wherein ring A is as defined above, or a salt thereof, and a compound of the formula:



wherein M^1 is an alkali metal atom or a group of the formula: $-Mg-Y^1$ [$+$] where Y^1 is a halogen atom, [$+$] and R is as defined above, or a salt thereof, bringing the resulting product into contact with an acid to give a compound of the formula:



wherein each symbol is as defined above, or a salt thereof, and then reacting this compound and a compound of the formula:



wherein M^2 is an alkali metal atom or a group of the formula: $-Mg-Y^2$ [$+$] where Y^2 is a halogen atom, [$+$] and other symbols are as defined above, or a salt thereof.

(5) (AMENDED) The production method described in claim (1), [~~(2)~~, ~~(3)~~ or ~~(4)~~], wherein the ring A of the compounds of the formulas

(I) and (III) [~~and~~ (V) ~~and~~ (VI)] is an imidazole ring wherein the 1- or 3-position is optionally protected.

(6) (AMENDED) The production method described in claim (1), [~~(2)~~, ~~(3)~~ ~~or~~ ~~(4)~~], wherein R is an optionally substituted lower alkyl group, an optionally substituted lower alkenyl group, an optionally substituted cycloalkyl group, an optionally substituted phenyl group or an optionally substituted pyridyl group.

(7) (AMENDED) The production method described in claim (1), [~~(2)~~, ~~(3)~~ ~~or~~ ~~(4)~~], wherein R is a lower alkenyl group, a cycloalkyl group, a phenyl group, a pyridyl group, or a lower alkyl group optionally substituted by a halogen atom.

(8) (AMENDED) The production method described in claim (1), [~~(2)~~, ~~(3)~~ ~~or~~ ~~(4)~~], wherein R is a C₁₋₆ alkyl group.

(9) (AMENDED) The production method described in claim (1), [~~(2)~~, ~~(3)~~ ~~or~~ ~~(4)~~], wherein R is an isopropyl group.

(10) (AMENDED) The production method described in claim (2), [~~(3)~~ ~~or~~ ~~(4)~~], wherein M² is sodium, potassium or a group of the formula:

-Mg-Y² [~~+~~] where Y² is a halogen atom[~~+~~].

(11) (AMENDED) The production method described in claim (1), [~~(3)~~ ~~or~~ ~~(4)~~], wherein the reaction product of a compound of the formula (I) or a salt thereof and a compound of the formula (II) or a salt thereof is brought into contact with a sulfuric acid.


(12) (AMENDED) The production method described in claim (1), [~~(3)~~ ~~or~~ ~~(4)~~], wherein not less than 3 equivalents of the compound of

the formula (II) or a salt thereof is used per one equivalent of the compound of the formula (I) or a salt thereof.

(13) (AMENDED) The production method described in claim (1), [~~(3)~~ or ~~(4)~~], wherein the compound of the formula (I) or a salt thereof and the compound of the formula (II) or a salt thereof are reacted in tetrahydrofuran.

(14) (AMENDED) The production method described in claim (1), [~~(3)~~ or ~~(4)~~], wherein the compound of the formula (I) or a salt thereof and the compound of the formula (II) or a salt thereof are reacted in not less than 50 equivalents of a solvent relative to one equivalent of the compound of the formula (I) or a salt thereof.

(15) A compound of the formula:



(IIIa)

wherein R' is an optionally substituted alkyl group having 3 or more carbon atoms, or a salt thereof.

(16) The compound of claim (15), wherein R' is an optionally substituted branched alkyl group having 3 or more carbon atoms.

(17) 1-(1H-Imidazol-4-yl)-2-methyl-1-propanone or a salt thereof.

NEW CLAIMS

(18) The production method described in claim (2), wherein the ring A of the compounds of the formulas (III) and (V) is an

imidazole ring wherein the 1- or 3-position is optionally protected.

(19) The production method described in claim (2), wherein R is an optionally substituted lower alkyl group, an optionally substituted lower alkenyl group, an optionally substituted cycloalkyl group, an optionally substituted phenyl group or an optionally substituted pyridyl group.

(20) The production method described in claim (2), wherein R is a lower alkenyl group, a cycloalkyl group, a phenyl group, a pyridyl group, or a lower alkyl group optionally substituted by a halogen atom.

(21) The production method described in claim (2), wherein R is a C₁₋₆ alkyl group.

(22) The production method described in claim (2), wherein R is an isopropyl group.

(23) The production method described in claim (3), wherein the ring A of the compounds of the formulas (I), (III), and (V) is an imidazole ring wherein the 1- or 3-position is optionally protected.

(24) The production method described in claim (3), wherein R is an optionally substituted lower alkyl group, an optionally substituted lower alkenyl group, an optionally substituted cycloalkyl group, an optionally substituted phenyl group or an optionally substituted pyridyl group.

(25) The production method described in claim (3), wherein R is a lower alkenyl group, a cycloalkyl group, a phenyl group, a

pyridyl group, or a lower alkyl group optionally substituted by a halogen atom.

(26) The production method described in claim (3), wherein R is a C₁₋₆ alkyl group.

(27) The production method described in claim (3), wherein R is an isopropyl group.

(28) The production method described in claim (3), wherein M^2 is sodium, potassium or a group of the formula:
 $-Mq-Y^2$ where Y^2 is a halogen atom.

(29) The production method described in claim (3), wherein the reaction product of a compound of the formula (I) or a salt thereof and a compound of the formula (II) or a salt thereof is brought into contact with a sulfuric acid.

(30) The production method described in claim (3), wherein not less than 3 equivalents of the compound of the formula (II) or a salt thereof is used per one equivalent of the compound of the formula (I) or a salt thereof.

(31) The production method described in claim (3), wherein the compound of the formula (I) or a salt thereof and the compound of the formula (II) or a salt thereof are reacted in tetrahydrofuran.

(32) The production method described in claim (3), wherein the compound of the formula (I) or a salt thereof and the compound of the formula (II) or a salt thereof are reacted in not less than 50 equivalents of a solvent relative to one equivalent of the compound of the formula (I) or a salt thereof.

(33) The production method described in claim (4), wherein the ring A of the compounds of the formulas (I), (III), (V) and (VI) is an imidazole ring wherein the 1- or 3-position is optionally protected.

(34) The production method described in claim (4), wherein R is an optionally substituted lower alkyl group, an optionally substituted lower alkenyl group, an optionally substituted cycloalkyl group, an optionally substituted phenyl group or an optionally substituted pyridyl group.

(35) The production method described in claim (1), (2), (3) or (4), wherein R is a lower alkenyl group, a cycloalkyl group, a phenyl group, a pyridyl group, or a lower alkyl group optionally substituted by a halogen atom.

(36) The production method described in claim (4), wherein R is a C₁₋₆ alkyl group.

(37) The production method described in claim (4), wherein R is an isopropyl group.

(38) The production method described in claim (4), wherein M² is sodium, potassium or a group of the formula:
-Mg-Y² where Y² is a halogen atom.

(39) The production method described in claim (4), wherein the reaction product of a compound of the formula (I) or a salt thereof and a compound of the formula (II) or a salt thereof is brought into contact with a sulfuric acid.

(40) The production method described in claim (4), wherein not

less than 3 equivalents of the compound of the formula (II) or a salt thereof is used per one equivalent of the compound of the formula (I) or a salt thereof.

(41) The production method described in claim (4), wherein the compound of the formula (I) or a salt thereof and the compound of the formula (II) or a salt thereof are reacted in tetrahydrofuran.

(42) The production method described in claim (4), wherein the compound of the formula (I) or a salt thereof and the compound of the formula (II) or a salt thereof are reacted in not less than 50 equivalents of a solvent relative to one equivalent of the compound of the formula (I) or a salt thereof.

REMARKS

The specification is amended above to insert a reference to related cases.

The claims have been reformatted to better conform the claims to US practice, in particular, multi-dependent claims have been amended and new dependent claims added directed to the same subject matter.

A mark-up of the claims showing the requested amendments is provided. Also provided for the Examiner's use is a clean set of claims as amended.

No amendment of inventorship is necessitated by these amendments.

Early allowance of the claims is requested. Should the Examiner believe that a conference with applicants' attorney would advance prosecution of this application, the Examiner is respectfully invited to call applicants' attorney.

Respectfully submitted,

Dated: December 20, 2001

(847)383-3372
(847)383-3391



Mark Chao, Ph.D., Reg. No. 37,293
Elaine M. Ramesh, Ph.D., Reg. No. 43032
Attorney for Applicants
Customer No. 23115

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
Suite 500, 475 Half Day Road
Lincolnshire, IL 60069 USA

$$\begin{aligned} & \begin{pmatrix} a_{11} & a_{12} \\ a_{21} & a_{22} \end{pmatrix} \begin{pmatrix} b_{11} & b_{12} \\ b_{21} & b_{22} \end{pmatrix} = \begin{pmatrix} a_{11}b_{11} & a_{11}b_{12} + a_{12}b_{21} & a_{11}b_{22} \\ a_{21}b_{11} & a_{21}b_{12} + a_{22}b_{21} & a_{21}b_{22} \end{pmatrix} \\ & \begin{pmatrix} a_{11} & a_{12} \\ a_{21} & a_{22} \end{pmatrix} \begin{pmatrix} b_{11} & b_{12} \\ b_{21} & b_{22} \end{pmatrix} = \begin{pmatrix} a_{11}b_{11} & a_{11}b_{12} + a_{12}b_{21} & a_{11}b_{22} \\ a_{21}b_{11} & a_{21}b_{12} + a_{22}b_{21} & a_{21}b_{22} \end{pmatrix} \end{aligned}$$

(1) (AMENDED) A method for producing a compound of the formula:



wherein R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group and ring A is an imidazole ring which is optionally substituted further, or a salt thereof, which method comprises reacting a compound of the formula:




wherein ring A is as defined above, or a salt thereof, and a compound of the formula:



wherein M¹ is an alkali metal atom or a group of the formula:
-Mg-Y¹ where Y¹ is a halogen atom, and R is as defined above, or
a salt thereof, and bringing the resulting product into contact
with an acid.

(2) (AMENDED) A method for producing a compound of the formula:




wherein R is an optionally substituted hydrocarbon group or an

optionally substituted heterocyclic group, ring A is an imidazole ring which is optionally substituted further, and R^1 , R^2 , R^3 , R^4 , R^5 , R^6 and R^7 are each independently a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted hydroxyl group, an optionally substituted thiol group, an optionally substituted amino group, an acyl group or a halogen atom, or a salt thereof, which method comprises reacting a compound of the formula:




wherein each symbol is as defined above, or a salt thereof, and a compound of the formula:



wherein M^2 is an alkali metal atom or a group of the formula: $-Mg-Y^1$ where Y^1 is a halogen atom, and other symbols are as defined above, or a salt thereof.

(3) (AMENDED) A method for producing a compound of the formula:



wherein R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, ring A is an imidazole ring which is optionally substituted further and R¹, R², R³, R⁴, R⁵, R⁶ and R⁷ are each independently a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted hydroxyl group, an optionally substituted thiol group, an optionally substituted amino group, an acyl group or a halogen atom, or a salt thereof, which method comprises reacting a compound of the formula:




wherein ring A is as defined above, or a salt thereof, and a compound of the formula:



wherein M¹ is an alkali metal atom or a group of the formula: -Mg-Y¹ where Y¹ is a halogen atom, and R is as defined above, or a salt thereof, and bringing the resulting product into contact with an acid to give a compound of the formula:




wherein each symbol is as defined above, or a salt thereof, and then reacting this compound and a compound of the formula:



wherein M² is an alkali metal atom or a group of the formula:

-Mg-Y² where Y² is a halogen atom, and other symbols are as defined above, or a salt thereof.

(4) (AMENDED) A method for producing a compound of the formula:




wherein R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, ring A is an imidazole ring which is optionally substituted further and R¹, R², R³, R⁴, R⁵, R⁶ and R⁷ are each independently a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted hydroxyl group, an optionally substituted thiol group, an optionally substituted amino group, an acyl group or a halogen atom, or a salt thereof, which method comprises reacting a compound of the formula:



wherein ring A is as defined above, or a salt thereof and hydroxylamine or a salt thereof, subjecting the resulting product to dehydration to give a compound of the formula:




wherein ring A is as defined above, or a salt thereof, and a compound of the formula:



wherein M^1 is an alkali metal atom or a group of the formula:
 $-Mg-Y^1$ where Y^1 is a halogen atom, and R is as defined above, or
 a salt thereof, bringing the resulting product into contact with
 an acid to give a compound of the formula:



wherein each symbol is as defined above, or a salt thereof, and
 then reacting this compound and a compound of the formula:



wherein M^2 is an alkali metal atom or a group of the formula:
 $-Mg-Y^2$ where Y^2 is a halogen atom, and other symbols are as
 defined above, or a salt thereof.


(5) (AMENDED) The production method described in claim (1),
 wherein the ring A of the compounds of the formulas (I) and (III)
 is an imidazole ring wherein the 1- or 3-position is optionally
 protected.

(6) (AMENDED) The production method described in claim (1),
 wherein R is an optionally substituted lower alkyl group, an
 optionally substituted lower alkenyl group, an optionally
 substituted cycloalkyl group, an optionally substituted phenyl
 group or an optionally substituted pyridyl group.

- (7) (AMENDED) The production method described in claim (1), wherein R is a lower alkenyl group, a cycloalkyl group, a phenyl group, a pyridyl group, or a lower alkyl group optionally substituted by a halogen atom.
- (8) (AMENDED) The production method described in claim (1), wherein R is a C₁₋₆ alkyl group.
- (9) (AMENDED) The production method described in claim (1), wherein R is an isopropyl group.
- (10) (AMENDED) The production method described in claim (2), wherein M² is sodium, potassium or a group of the formula: -Mg-Y² where Y² is a halogen atom.
- (11) (AMENDED) The production method described in claim (1), wherein the reaction product of a compound of the formula (I) or a salt thereof and a compound of the formula (II) or a salt thereof is brought into contact with a sulfuric acid.
- (12) (AMENDED) The production method described in claim (1), wherein not less than 3 equivalents of the compound of the formula (II) or a salt thereof is used per one equivalent of the compound of the formula (I) or a salt thereof.
- (13) (AMENDED) The production method described in claim (1), wherein the compound of the formula (I) or a salt thereof and the compound of the formula (II) or a salt thereof are reacted in tetrahydrofuran.
- (14) (AMENDED) The production method described in claim (1), wherein the compound of the formula (I) or a salt thereof and the compound of the formula (II) or a salt thereof are reacted in not

less than 50 equivalents of a solvent relative to one equivalent of the compound of the formula (I) or a salt thereof.

(15) A compound of the formula:



(IIIa)

wherein R' is an optionally substituted alkyl group having 3 or more carbon atoms, or a salt thereof.

(16) The compound of claim (15), wherein R' is an optionally substituted branched alkyl group having 3 or more carbon atoms.

(17) 1-(1H-Imidazol-4-yl)-2-methyl-1-propanone or a salt thereof.

(18) The production method described in claim (2), wherein the ring A of the compounds of the formulas (III) and (V) is an imidazole ring wherein the 1- or 3-position is optionally protected.

(19) The production method described in claim (2), wherein R is an optionally substituted lower alkyl group, an optionally substituted lower alkenyl group, an optionally substituted cycloalkyl group, an optionally substituted phenyl group or an optionally substituted pyridyl group.

(20) The production method described in claim (2), wherein R is a lower alkenyl group, a cycloalkyl group, a phenyl group, a pyridyl group, or a lower alkyl group optionally substituted by a halogen atom.

(21) The production method described in claim (2), wherein R is a C₁₋₆ alkyl group.

(22) The production method described in claim (2), wherein R is an isopropyl group.

(23) The production method described in claim (3), wherein the ring A of the compounds of the formulas (I), (III), and (V) is an imidazole ring wherein the 1- or 3-position is optionally protected.

(24) The production method described in claim (3), wherein R is an optionally substituted lower alkyl group, an optionally substituted lower alkenyl group, an optionally substituted cycloalkyl group, an optionally substituted phenyl group or an optionally substituted pyridyl group.

(25) The production method described in claim (3), wherein R is a lower alkenyl group, a cycloalkyl group, a phenyl group, a pyridyl group, or a lower alkyl group optionally substituted by a halogen atom.

(26) The production method described in claim (3), wherein R is a C₁₋₆ alkyl group.

(27) The production method described in claim (3), wherein R is an isopropyl group.

(28) The production method described in claim (3), wherein M² is sodium, potassium or a group of the formula:
-Mg-Y² where Y² is a halogen atom.

(29) The production method described in claim (3), wherein the

reaction product of a compound of the formula (I) or a salt thereof and a compound of the formula (II) or a salt thereof is brought into contact with a sulfuric acid.

(30) The production method described in claim (3), wherein not less than 3 equivalents of the compound of the formula (II) or a salt thereof is used per one equivalent of the compound of the formula (I) or a salt thereof.

(31) The production method described in claim (3), wherein the compound of the formula (I) or a salt thereof and the compound of the formula (II) or a salt thereof are reacted in tetrahydrofuran.

(32) The production method described in claim (3), wherein the compound of the formula (I) or a salt thereof and the compound of the formula (II) or a salt thereof are reacted in not less than 50 equivalents of a solvent relative to one equivalent of the compound of the formula (I) or a salt thereof.

(33) The production method described in claim (4), wherein the ring A of the compounds of the formulas (I), (III), (V) and (VI) is an imidazole ring wherein the 1- or 3-position is optionally protected.

(34) The production method described in claim (4), wherein R is an optionally substituted lower alkyl group, an optionally substituted lower alkenyl group, an optionally substituted cycloalkyl group, an optionally substituted phenyl group or an optionally substituted pyridyl group.

(35) The production method described in claim (1), (2), (3) or (4), wherein R is a lower alkenyl group, a cycloalkyl group, a

phenyl group, a pyridyl group, or a lower alkyl group optionally substituted by a halogen atom.

(36) The production method described in claim (4), wherein R is a C₁₋₆ alkyl group.

(37) The production method described in claim (4), wherein R is an isopropyl group.

(38) The production method described in claim (4), wherein M² is sodium, potassium or a group of the formula:
-Mg-Y² where Y² is a halogen atom.

(39) The production method described in claim (4), wherein the reaction product of a compound of the formula (I) or a salt thereof and a compound of the formula (II) or a salt thereof is brought into contact with a sulfuric acid.

(40) The production method described in claim (4), wherein not less than 3 equivalents of the compound of the formula (II) or a salt thereof is used per one equivalent of the compound of the formula (I) or a salt thereof.

(41) The production method described in claim (4), wherein the compound of the formula (I) or a salt thereof and the compound of the formula (II) or a salt thereof are reacted in tetrahydrofuran.

(42) The production method described in claim (4), wherein the compound of the formula (I) or a salt thereof and the compound of the formula (II) or a salt thereof are reacted in not less than 50 equivalents of a solvent relative to one equivalent of the compound of the formula (I) or a salt thereof.

DESCRIPTION

PRODUCTION METHOD OF IMIDAZOLE DERIVATIVES


Technical field

The present invention relates to a production method of
5 a naphthalene derivative showing a pharmaceutical effect such
as a steroid C_{17,20} lyase inhibitory action and the like, and an
intermediate therefor.

Background Art


As a synthetic method of a compound wherein an aromatic
10 compound is substituted by an alkanoyl group, for example, the
following reactions are known.

(1) JP-A-7-285945 discloses a reaction shown by



15 wherein R₁ and R₂ are each a hydrogen atom, a halogen atom, an
alkyl group and the like, and R₃ is a hydrogen atom, an alkyl
group, an aryl group and the like,


(2) Tetrahedron 49(7), 1431 (1993) discloses a reaction shown
by



20

and

(3) J. Org. Chem. 59(17), 4844 (1994) discloses a reaction
shown by



Disclosure of the Invention

The present inventors have conducted intensive studies of a production method of the compound of the following formula (V) having a superior steroid C_{17,20} lyase inhibitory action and the like and an intermediate therefor, and found that the synthesis of a compound of the following formula (V) from a compound of the following formula (VI) via a compound of the following formula (I) and a compound of the following formula (III) unexpectedly leads to an industrially advantageous production of a compound of the following formula (V), by which the compound can be obtained in a high yield with a less number of steps without using a heavy metal compound.

Accordingly, the present invention relates to:

(1) a method for producing a compound of the formula:



wherein R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group and ring A is an imidazole ring which may be further substituted, or a salt thereof, which method comprises reacting a compound of the formula:




wherein ring A is as defined above, or a salt thereof, and a

compound of the formula:




wherein M^1 is an alkali metal atom or a group of the formula:
 $-Mg-Y^1$ (Y^1 is a halogen atom) and R is as defined above, or a
 5 salt thereof, and bringing the resulting product into contact
 with an acid;

(2) a method for producing a compound of the formula:



10

wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^6 and R^7 are each independently a
 hydrogen atom, an optionally substituted hydrocarbon group, an
 optionally substituted hydroxyl group, an optionally
 substituted thiol group, an optionally substituted amino group,
 15 an acyl group or a halogen atom and other symbols are as
 defined above, or a salt thereof, which method comprises
 reacting a compound of the formula (III) or a salt thereof and
 a compound of the formula:



20


wherein M^2 is an alkali metal atom or a group of the formula:
 $-Mg-Y^2$ (Y^2 is a halogen atom) and other symbols are as defined
 above, or a salt thereof;

(3) a method for producing a compound of the formula (V) or a

17
 salt thereof, which method comprises reacting a compound of the formula (I) or a salt thereof and a compound of the formula (II) or a salt thereof, bringing the resulting product into contact with an acid to give a compound of the formula (III) or
 5 a salt thereof, and then reacting this compound and a compound of the formula (IV) or a salt thereof;

(4) a method for producing a compound of the formula (V) or a salt thereof, which method comprises reacting a compound of the formula:

10



(VI)

wherein ring A is as defined above, or a salt thereof, and hydroxylamine or a salt thereof, subjecting the resulting product to dehydration to give a compound of the formula (I) or
 15 a salt thereof, reacting this compound and a compound of the formula (II) or a salt thereof, bringing the resulting product into contact with an acid to give a compound of the formula (III) or a salt thereof, and reacting this compound and a compound of the formula (IV) or a salt thereof;

20 (5) the production method described in the above-mentioned (1), (2), (3) or (4), wherein the ring A of the compounds of the formulas (I), (III), (V) and (VI) is an imidazole ring wherein the 1- or 3-position is optionally protected;

(6) the production method described in the above-mentioned (1),
 25 (2), (3) or (4), wherein R is an optionally substituted lower alkyl group, an optionally substituted lower alkenyl group, an optionally substituted cycloalkyl group, an optionally substituted phenyl group or an optionally substituted pyridyl group;

30 (7) the production method described in the above-mentioned (1), (2), (3) or (4), wherein R is a lower alkenyl group, a cycloalkyl group, a phenyl group, a pyridyl group, or a lower

alkyl group optionally substituted by a halogen atom;

(8) the production method described in the above-mentioned (1), (2), (3) or (4), wherein R is a C₁₋₆ alkyl group;

(9) the production method described in the above-mentioned (1), (2), (3) or (4), wherein R is an isopropyl group;

(10) the production method described in the above-mentioned (2), (3) or (4), wherein M² is sodium, potassium or a group of the formula: -Mg-Y² (Y² is a halogen atom);


(11) the production method described in the above-mentioned (1), (3) or (4), wherein the reaction product of a compound of the formula (I) or a salt thereof and a compound of the formula (II) or a salt thereof is brought into contact with a sulfuric acid;

(12) the production method described in the above-mentioned (1), (3) or (4), wherein not less than 3 equivalents of the compound of the formula (II) or a salt thereof is used per one equivalent of the compound of the formula (I) or a salt thereof;

(13) the production method described in the above-mentioned (1), (3) or (4), wherein the compound of the formula (I) or a salt thereof and the compound of the formula (II) or a salt thereof are reacted in tetrahydrofuran;

(14) the production method described in the above-mentioned (1), (3) or (4) wherein the compound of the formula (I) or a salt thereof and the compound of the formula (II) or a salt thereof are reacted in not less than 50 equivalents of a solvent relative to one equivalent of the compound of the formula (I) or a salt thereof;

(15) a compound of the formula:



(IIIa)


(16) the compound of the above-mentioned (15), wherein R' is an optionally substituted branched alkyl group having 3 or more
5 carbon atoms;

(17) 1-(1H-imidazol-4-yl)-2-methyl-1-propanone or a salt thereof; and the like.

In the above-mentioned formulas, the alkali metal atom shown by M^1 and M^2 includes, for example, sodium atom, potassium atom, lithium atom and the like.

The halogen atom shown by Y¹ and Y² includes, for example, fluorine atom, chlorine atom, bromine atom, iodine atom and the like.

In the above-mentioned formulas (I), (III), (IIIa), (V)
15 and (VI), the ring A is an imidazole ring which may be further
substituted, and the formula:



and may have additional substituent(s) besides the
20 substituent(s) already present on the ring.

6

(e.g., fluorine, chlorine, bromine, iodine etc.), nitro group, methoxy group and the like, wherein the number of the substituent(s) is generally 1 to 3. These protecting groups can be removed easily by hydrolysis, oxidation, reduction and a typical removing method. The group that substitutes carbon atom of the ring A includes, for example, an optionally substituted lower alkyl group, an optionally substituted lower alkoxy group, an optionally substituted alkylsulfonyl group, an optionally substituted carbamoyl group, an optionally substituted sulfamoyl group and the like. The optionally substituted lower alkyl includes, for example, unsubstituted C₁₋₄ alkyl group such as methyl, ethyl, propyl and the like, and alkyl group having substituent(s) such as halogeno-C₁₋₄ alkyl group and the like, which is exemplified by bromomethyl, difluoroethyl and the like. The optionally substituted lower alkoxy group includes unsubstituted C₁₋₄ alkoxy group such as methoxy, ethoxy, propoxy, isopropoxy and the like, and alkoxy group having substituent(s) such as halogeno-C₁₋₄ alkoxy group and the like, which is exemplified by chloromethoxy, bromoethoxy and the like. The optionally substituted alkylsulfonyl group includes, for example, unsubstituted C₁₋₄ alkylsulfonyl group such as methylsulfonyl, ethylsulfonyl and the like, and alkylsulfonyl group having substituent(s) such as C₁₋₄ alkoxy-C₁₋₄ alkylsulfonyl group and the like, which is exemplified by methoxymethylsulfonyl and the like. The optionally substituted carbamoyl group includes, for example, besides the unsubstituted carbamoyl group, carbamoyl group having substituent(s) such as mono- or di-C₁₋₄ alkylcarbamoyl group (e.g., methylcarbamoyl, ethylcarbamoyl, dimethylcarbamoyl, diethylcarbamoyl etc.), mono- or di-C₆₋₁₄ arylcarbamoyl group (e.g., phenylcarbamoyl, diphenylcarbamoyl etc.), mono- or di-C₇₋₁₆ aralkylcarbamoyl group (e.g., benzylcarbamoyl, dibenzylcarbamoyl etc.) and the like. The optionally substituted sulfamoyl group includes, for example, besides the

The "aromatic hydrocarbon group" may be, for example, monocyclic aromatic hydrocarbon group or fused polycyclic aromatic hydrocarbon group consisting of 6 to 18 carbon atoms, and the like. Specific examples include C₆₋₁₄ aryl group such as phenyl, 1-naphthyl, 2-naphthyl, 2-indenyl, 2-anthryl and the like, with preference given to C₆₋₁₀ aryl group (e.g., phenyl etc.) and the like.

The substituent that the "hydrocarbon group" of the "optionally substituted hydrocarbon group" may have is(are) not particularly limited as long as the object of the present invention is achieved. For example, halogen atom, hydroxy group, alkoxy group, acyloxy group, alkylthio group, alkylsulfonyl group, mono- or di-alkylamino group, acylamino group, carboxyl group, alkoxycarbonyl group, oxo group, cycloalkyl group, aryl group, aromatic heterocyclic group and the like are mentioned. These substituents are present at chemically acceptable positions on the "hydrocarbon group" and the number of the substituent(s) is 1 to 5, preferably 1 to 3. When the number of the substituents is 2 or more, they may be the same or different.

When the "hydrocarbon group" of the "optionally substituted hydrocarbon group" is a "hydrocarbon chain group", the substituent(s) that the "hydrocarbon chain group" may have is(are) not particularly limited as long as the object of the

present invention is achieved. For example, halogen atom, hydroxy group, alkoxy group, acyloxy group, alkylthio group, acylamino group, carboxyl group, alkoxycarbonyl group, cycloalkyl group, aryl group, aromatic heterocyclic group and
 5 the like are mentioned. These substituents are present at chemically acceptable positions on the "hydrocarbon chain group" and the number of the substituent(s) is 1 to 5, preferably 1 to 3. When the number of the substituents is 2 or more, they may be the same or different.

10 When the "hydrocarbon group" of the "optionally substituted hydrocarbon group" is a "cyclic hydrocarbon group", the substituent(s) that the "cyclic hydrocarbon group" may have is(are) not particularly limited as long as the object of the present invention is achieved. For example, halogen atom, oxo
 15 group, hydroxy group, alkoxy group, acyloxy group, alkylthio group, alkylsulfonyl group, mono- or di-alkylamino group, acylamino group, carboxyl group, alkoxycarbonyl group, alkyl group, cycloalkyl group, aryl group, aromatic heterocyclic group and the like are mentioned. These substituents are
 20 present at chemically acceptable positions on the "cyclic hydrocarbon group" and the number of the substituent(s) is 1 to 5, preferably 1 to 3. When the number of the substituents is 2 or more, they may be the same or different.

The "halogen atom" used as the "substituent" of the
 25 "optionally substituted hydrocarbon group" includes, for example, fluorine, chlorine, bromine, iodine and the like, the "alkoxy group" includes, for example, C₁₋₁₀ alkoxy group such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy, hexyloxy and the like, and the like, the
 30 "acyloxy group" includes, for example, C₁₋₁₀ alkyl-carbonyloxy (e.g., acetoxy, propionyloxy etc.) and the like, the "alkylthio group" includes, for example, C₁₋₁₀ alkylthio group such as methylthio, ethylthio, propylthio, isopropylthio and the like, and the like, the "alkylsulfonyl group" includes, for example,

C₁₋₁₀ alkylsulfonyl group such as methylsulfonyl, ethylsulfonyl, propylsulfonyl and the like, and the like, the mono- or di-alkylamino group includes, for example, C₁₋₄ alkylamino group such as methylamino, ethylamino, propylamino and the like, di-
 5 C₁₋₄ alkylamino group such as dimethylamino, diethylamino and the like, the "acylamino group" includes, for example, mono- or di-C₁₋₁₀ alkyl-carbonylamino (e.g., acetylamino, propionylamino, butyrylamino, diacetylamino etc.) and the like, the "alkoxycarbonyl group" includes, for example, C₁₋₁₀ alkoxy-
 10 carbonyl group such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl and the like, and the like, the "cycloalkyl group" includes, for example, C₃₋₁₀cycloalkyl group such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like, and the like, the "aryl group" includes, for example, C₆₋₁₄ aryl group such as phenyl,
 15 1-naphthyl, 2-naphthyl and the like, and the like, the "aromatic heterocyclic group" includes, for example, mono to tricyclic aromatic heterocyclic group having, besides the carbon atom, 1 or 2 kinds of preferably 1 to 4 heteroatom(s)
 20 selected from nitrogen, oxygen and sulfur, and the like. Specific examples include thienyl, pyridyl, furylpyrazinyl, pyrimidinyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isooxazolyl, pyridazinyl, tetrazolyl, quinolyl, indolyl, isoindolyl and the like. The "alkyl group" includes,
 25 for example, C₁₋₁₀ alkyl group such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl and the like, and the like.

Of the substituents that the aforementioned "hydrocarbon group" may have, alkoxy group, acyloxy group, alkylthio group,
 30 alkylsulfonyl group, mono- or di- alkylamino group, acylamino group, carboxyl group, alkoxycarbonyl group, alkyl group, cycloalkyl group, aryl group and aromatic heterocyclic group may further have 1 to 5, preferably 1 to 3, additional substituent(s) at chemically acceptable position(s). Such

substituents include, for example, halogen atom (e.g., fluorine, chlorine, bromine etc.), hydroxy group and C₁₋₆ alkoxy group (e.g., methoxy, ethoxy, propoxy, isopropoxy etc.).

The heterocyclic group of the "optionally substituted heterocyclic group" shown by R may be, for example, a saturated or unsaturated 4 to 8-membered monocyclic heterocyclic group having, as an atom constituting the ring besides the carbon atom, at least one, preferably 1 to 4, heteroatom(s) such as nitrogen atom, sulfur atom, oxygen atom and the like, or a fused heterocyclic group thereof. Examples thereof include thienyl(2-thienyl, 3-thienyl), pyridyl(2-pyridyl, 3-pyridyl, 4-pyridyl), furyl(2-furyl, 3-furyl), pyrazinyl, 2-pyrimidinyl, 3-pyrrolyl, imidazolyl(1-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl), 1-pyrazolyl, thiazolyl(2-thiazolyl, 4-thiazolyl, 5-thiazolyl), isothiazolyl(3-isothiazolyl, 4-isothiazolyl), oxazolyl(2-oxazolyl, 4-oxazolyl, 5-oxazolyl), isooxazolyl(3-isooxazolyl), 3-pyridazinyl, benzothienyl and the like. Of these, a monocyclic aromatic heterocyclic group, such as 2-pyridyl, 3-pyridyl, 4-pyridyl, 1-imidazolyl, 4-imidazolyl and the like, is preferable.

The substituent of the "optionally substituted heterocyclic group" shown by R may have 1 to 3 substituent(s) at substitutable position(s) of the heterocyclic group. The substituent may be, for example, alkyl group optionally substituted by 1 to 5 halogen atom(s) (e.g., fluorine, chlorine, bromine, iodine) [e.g., C₁₋₄ alkyl such as methyl, ethyl, propyl and the like, halogeno C₁₋₄ alkyl such as 2,2,2-trifluoroethyl, 2,2,3,3,3-pentafluoropropyl and the like), C₁₋₄ alkoxy group such as methoxy, ethoxy, propoxy, isopropoxy and the like, halogen atom such as chlorine atom, fluorine atom and the like, hydroxy group, amino group, nitro group and the like.

Examples of preferable R include, of the aforementioned examples, an optionally substituted lower alkyl group (having 1 to 4 carbon atoms), an optionally substituted lower alkenyl

group (having 1 to 4 carbon atoms), an optionally substituted cycloalkyl group (having 3 to 6 carbon atoms), an optionally substituted phenyl group and an optionally substituted pyridyl group, with particular preference given to lower alkenyl group
 5 (having 1 to 4 carbon atoms), cycloalkyl group (having 3 to 6 carbon atoms), phenyl group, pyridyl group and lower alkyl group (having 1 to 4 carbon atoms) optionally substituted by halogen.

The "optionally substituted alkyl group having not less
 10 than 3 carbon atoms" shown by R' may be, for example, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, isopentyl, n-hexyl, n-heptyl, n-octyl and the like, with preference given to those having 3 to 6 carbon atoms.

The substituent, which the "alkyl group having not less
 15 than 3 carbon atoms" of the "optionally substituted alkyl group having not less than 3 carbon atoms" shown by R' has, is exemplified by those mentioned with regard to the aforementioned substituents of the "hydrocarbon group" of the "optionally substituted hydrocarbon group" shown by R. As R',
 20 unsubstituted alkyl group having not less than 3 carbon atoms is preferable.

The optionally substituted hydroxyl group shown by R¹, R², R³, R⁴, R⁵, R⁶ and R⁷ is, for example, besides the unsubstituted hydroxyl group, a substituted hydroxyl group, including, for
 25 example, an optionally substituted lower alkoxy such as (1) unsubstituted C₁₋₄ alkoxy group (e.g., methoxy, ethoxy, propoxy etc.), (2) lower alkoxy(lower)alkoxy group (C₁₋₄ alkoxy-C₁₋₄ alkoxy group) (e.g., methoxymethoxy, ethoxymethoxy, methoxyethoxy, ethoxyethoxy etc.), (3) lower
 30 alkanoyloxy(lower)alkoxy group (C₁₋₄ alkanoyloxy-C₁₋₄ alkoxy group) (e.g., acetyloxymethoxy, propionyloxymethoxy, acetyloxyethoxy, propionyloxyethoxy etc.), and the like, and (4) lower (C₁₋₄) alkoxy group optionally substituted by 1 to 4 fluorine atom(s) (e.g., fluoromethoxy, difluoromethoxy,

10 The optionally substituted thiol group shown by R¹, R²,
R³, R⁴, R⁵, R⁶ and R⁷ may be, for example, besides the
unsubstituted thiol group, substituted thiol group such as
lower alkylthio (e.g., C₁₋₄ alkylthio group such as methylthio,
ethylthio, propylthio and the like), lower alkanoylthio (e.g.,
15 C₁₋₄ alkanoylthio such as acetylthio, propionylthio and the
like), and the like.

The optionally substituted amino group shown by R¹, R², R³, R⁴, R⁵, R⁶ and R⁷ may be, for example, besides the unsubstituted amino group, substituted amino group such as lower alkylamino (e.g., C₁₋₄ alkylamino group such as methylamino, ethylamino, propylamino and the like), di(lower)alkylamino (e.g., di(C₁₋₄)alkylamino such as dimethylamino, diethylamino and the like), C₁₋₄ alkanoylamino (e.g., acetamide, propionamide etc.) and the like.

25 The acyl group shown by R¹, R², R³, R⁴, R⁵, R⁶ and R⁷ may be, for example, alkylsulfonyl group (e.g., C₁₋₄ alkylsulfonyl such as methylsulfonyl, ethylsulfonyl and the like), an optionally substituted carbamoyl group such as mono- or di(C₁₋₁₀)alkylcarbamoyl group (e.g., methylcarbamoyl, ethylcarbamoyl, 30 propylcarbamoyl, isopropylcarbamoyl, cyclopropylcarbamoyl, dimethylcarbamoyl, diethylcarbamoyl etc.), mono- or di(C₆₋₁₄)arylcarbamoyl (e.g., phenylcarbamoyl, diphenylcarbamoyl etc.), mono- or di(C₇₋₁₆)aralkylcarbamoyl group (e.g., benzylcarbamoyl, dibenzylcarbamoyl etc.), an optionally

substituted sulfamoyl such as mono- or di(C₁₋₁₀)alkylsulfamoyl group (e.g., methylsulfamoyl, ethylsulfamoyl, dimethylsulfamoyl, diethylsulfamoyl etc.), mono- or di(C₆₋₁₄)arylsulfamoyl group (e.g., phenylsulfamoyl, diphenylsulfamoyl etc.), mono- or
 5 di(C₇₋₁₆)aralkylsulfamoyl group (e.g., benzylsulfamoyl, dibenzylsulfamoyl etc.), and the like.

The halogen shown by R¹, R², R³, R⁴, R⁵, R⁶ and R⁷ is exemplified by fluorine, chlorine, bromine, iodine and the like.

The "optionally substituted hydrocarbon group" shown by
 10 R¹, R², R³, R⁴, R⁵, R⁶ and R⁷ is exemplified by those similar to the "optionally substituted hydrocarbon group" shown by R. Of those, an optionally substituted lower alkyl group is preferable, which is exemplified by optionally substituted chain or cyclic C₁₋₆ alkyl group (e.g., methyl, ethyl, propyl,
 15 isopropyl, cyclopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, cyclopentyl, hexyl etc.). The C₁₋₆ alkyl group may have 1 to 5 substituent(s) at substitutable position(s). Examples of the substituent include, halogen (e.g., fluorine, chlorine, bromine etc.), C₁₋₄ alkoxy group (e.g., methoxy, ethoxy, propoxy
 20 etc.), hydroxyl group and the like.

Examples of preferable R¹, R², R³, R⁴, R⁵, R⁶ and R⁷ include hydrogen atom, optionally substituted hydrocarbon group, optionally substituted hydroxyl group, optionally substituted amino group and halogen atom from among those mentioned above,
 25 more preferably hydrogen atom, optionally substituted hydrocarbon group, optionally substituted hydroxyl group and halogen atom.

Of those mentioned above, R⁵ is preferably (1) an optionally substituted hydroxyl group such as (i) lower
 30 alkanoyloxy group, (ii) lower alkanoyloxy(lower)alkoxy group, (iii) lower alkoxy group, (iv) lower alkoxy(lower)alkoxy group, (v) lower alkoxy group optionally substituted by 1 to 4 fluorine atom(s) and (vi) benzyloxy group etc.), (2) a halogen atom, (3) a lower alkyl group optionally substituted by

hydroxyl group, (4) a lower alkynyl group, (5) a lower alkanoyl group, (6) an amino group optionally substituted by lower alkanoyl group, lower alkylaminocarbonyl group and lower alkylsulfonyl group, (7) lower alkylthio group or (8) mono- or di(C₁₋₁₀)alkylcarbamoyl, more preferably a lower alkyl group, a lower alkoxy group, a lower alkanoylamino group or a mono- or di(C₁₋₁₀)alkylcarbamoyl, and most preferably, a methoxy group. R⁶ is preferably a hydrogen atom, a lower alkyl group or a lower alkoxy, more preferably, a hydrogen atom or a lower alkoxy. R⁴ is preferably (1) a hydrogen atom, (2) a halogen atom, (3) a lower alkoxy group or (4) a lower alkyl group optionally substituted by hydroxyl group, more preferably, a hydrogen atom or a lower alkyl group.

As the combination of R¹, R², R³, R⁴, R⁵, R⁶ and R⁷, it is
15 preferable that 1 to 3 thereof be each independently an
optionally substituted lower alkyl group, an optionally
substituted hydroxyl group, an optionally substituted amino
group or a halogen atom, and it is more preferable that 1 to 3
thereof be each independently an optionally substituted lower
20 alkyl group or an optionally substituted hydroxyl group.

It is preferable that any of R⁴, R⁵ and R⁶ be a lower alkyl group or a lower alkoxy group, and all of R¹, R², R³ and R⁷ be each a hydrogen atom.

In the compounds of the above-mentioned formulas (I),
25 (II), (III), (IIIa), (IV), (V) and (VI), when the substituent
of the substituent shown by R, R', R¹, R², R³, R⁴, R⁵, R⁶ and R⁷
or the substituent of ring A has an amino group, a hydroxyl
group or a carboxyl group, it may be protected by a group known
to be a protecting group thereof.

30 The amino-protecting group is exemplified by those mentioned above with regard to the group that substitutes on the nitrogen atom as an atom constituting the ring in the aforementioned ring A.

The carboxyl-protecting group includes, for example,

optionally substituted, C₁₋₆ alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, tert-butyl etc.), phenyl, trityl, silyl and the like. These substituents may be halogen atom (e.g., fluorine, chlorine etc.), nitro group and the like, and the number of the substituent(s) is generally 1 to 3.

The hydroxy-protecting group includes, for example, optionally substituted, C₁₋₆ alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, tert-butyl etc.), phenyl, C₇₋₁₀ aralkyl (e.g., phenyl-C₁₋₄ alkyl such as benzyl and the like), phenyloxycarbonyl, benzoyl, (C₇₋₁₀ aralkyloxy)carbonyl (e.g., phenyl-C₁₋₄ alkyloxy-carbonyl such as benzyloxycarbonyl and the like), pyranyl, furanyl or silyl and the like. These substituents may be a halogen atom (e.g., fluorine, chlorine etc.), C₁₋₆ alkyl (e.g., methyl, ethyl, propyl etc.), phenyl, C₇₋₁₀ aralkyl (e.g., phenyl-C₁₋₄ alkyl such as benzyl and the like), nitro group and the like and the number of the substituent(s) is generally 1 to 4.

Unless otherwise specified, the "lower" in lower alkyl group, lower alkoxy group and the like in the present specification means chain, branched or ring having 1 to 6 carbon atoms.

A compound of the formula (III) or a salt thereof [hereinafter sometimes to be simply referred to as compound (III)] can be produced by reacting a compound of the formula (I) or a salt thereof [hereinafter sometimes to be simply referred to as compound (I)] and a compound of the formula (II) or a salt thereof [hereinafter sometimes to be simply referred to as compound (II)], and bringing the resulting product into contact with an acid.

30 Since the compounds of the formulas (I) and (III) contain a nitrogen atom as an atom constituting the ring A, they can form a salt. Such salt is, for example, inorganic acid salts such as hydrochloride, sulfate, hydrobromate, phosphate and the like, organic acid salts such as acetate,

trifluoroacetate, succinate, maleate, fumarate, propionate, citrate, tartrate, lactate, oxalate, methanesulfonate, p-toluenesulfonate and the like. When the substituent of the ring A in the formula (I), R in the formula (II), or R or ring A in the formula (III) has an acidic group such as carboxyl group and the like, these compounds can form, for example, alkali metal salt such as potassium salt, sodium salt, lithium salt and the like, alkaline earth metal salt such as calcium salt, magnesium salt and the like, salt with organic base such as ammonium salt, trimethylamine salt, triethylamine salt, tert-butyldimethylamine salt, dibenzylmethylamine salt, benzyldimethylamine salt, N,N-dimethylaniline salt, pyridine salt, quinoline salt and the like.

The reaction between compound (I) and compound (II) is generally carried out in a solvent. Examples of the solvent include an organic solvent inert to the reaction, such as ethers (e.g., diethyl ether, dioxane, tetrahydrofuran etc.), saturated hydrocarbons (e.g., hexane, pentane etc.), aromatic hydrocarbons (e.g., benzene, toluene etc.), halogenated hydrocarbons (e.g., dichloromethane, chloroform etc.) and the like. Of these, ethers such as tetrahydrofuran and the like are preferable. The amount of the solvent to be used is generally about 1-150 equivalents, particularly 50 to 60 equivalents, per 1 equivalent of compound (I). The amount of the compound (II) to be used is generally about 1 to 20 equivalents, preferably not less than 3 equivalents, particularly preferably 3 to 3.2 equivalents, per 1 equivalent of compound (I). The reaction temperature is from -20°C to 100°C, preferably 10 to 50°C, and the reaction time is about 5 minutes to 48 hours, preferably 1 to 5 hours. The product resulting from this reaction may be used as a starting material of the next reaction, after isolation by a conventional method or as a reaction mixture.

The obtained product is brought into contact with an

acid to produce compound (III).

The acid is, for example, inorganic acid such as hydrochloric acid, sulfuric acid and the like. Of these, sulfuric acid is preferable. In this case, addition of water
5 to the reaction system generally promotes the reaction and is preferable. The amount of acid to be added is generally 1 to 50 equivalents, preferably not less than 3 equivalents (3 to 10 equivalents), per 1 equivalent of compound (I), and the amount of water to be added is not less than 1 equivalent, preferably
10 not less than 3 equivalents, per 1 equivalent of compound (I). These acids are brought into contact with the resulting product generally by adding an aqueous solution (aqueous solution having an acid concentration of generally 1 to 80 wt%, preferably 5 to 20 wt%) to the reaction mixture containing the
15 product. The use of aqueous sulfuric acid solution (aqueous solution having an acid concentration of generally 1 to 80 wt%, preferably 5 to 20 wt%, 3 to 4 equivalents by conversion to sulfuric acid) per 1 equivalent of compound (I) is preferable.

When compound (III) thus obtained is in a free state, it
20 may be converted to a salt by a conventional method. When the compound is obtained as a salt, it may be converted to a free compound or a different salt by a conventional method. When the compound has a protecting group, it may be deprotected by a conventional method to be mentioned below. The compound (III)
25 thus obtained can be isolated and purified from a reaction mixture by a known method, such as redissolution, concentration, solvent extraction, fractional distillation, crystallization, recrystallization, chromatography and the like. Alternatively, it can be subjected to the next step as a reaction mixture
30 without isolation. The compound of the formula (IIIa) or a salt thereof [hereinafter sometimes to be simply referred to as compound (IIIa)] contained in the objective compound (III) of this reaction is a novel compound. Of the compounds (IIIa), a compound wherein R' is an optionally substituted branched alkyl

having not less than 3 carbon atoms (e.g., C₃₋₆ alkyl such as isopropyl, isobutyl, t-butyl, sec-butyl etc.) is preferable, and particularly 1-(1H-imidazol-4-yl)-2-methyl-1-propanone and a salt thereof are preferable. The compound (III) is useful as
5 a synthetic intermediate for various compounds.

A compound of the formula (V) or a salt thereof [hereinafter sometimes to be simply referred to as compound (V)] can be produced by reacting compound (III) and a compound of the formula (IV) or a salt thereof [hereinafter sometimes to
10 be simply referred to as compound (IV)]. Since the compound of the formula (V) contains a nitrogen atom as an atom constituting the ring A, it can form a salt. Examples of such salt include inorganic acid salts such as hydrochloride, sulfate, hydrobromate, phosphate and the like, and organic acid
15 salts such as acetate, trifluoroacetate, succinate, maleate, fumarate, propionate, citrate, tartrate, lactate, oxalate, methanesulfonate, p-toluenesulfonate and the like. When the substituents of R¹, R², R³, R⁴, R⁵, R⁶ and R⁷ in the formula (IV), the substituents of R, R¹, R², R³, R⁴, R⁵, R⁶ and R⁷ in the
20 formula (V) or the substituent of ring A has an acidic group, such as carboxyl group and the like, these compounds can form, for example, alkali metal salts such as potassium salt, sodium salt, lithium salt and the like, alkaline earth metal salts such as calcium salt, magnesium salt and the like, salts with
25 organic base such as ammonium salt, trimethylamine salt, triethylamine salt, tert-butyldimethylamine salt, dibenzylmethylamine salt, benzyldimethylamine salt, N,N-dimethylaniline salt, pyridine salt, quinoline salt and the like.

30 The reaction between compound (III) and compound (IV) is preferably carried out generally in a solvent. Examples of the solvent include an organic solvent inert to the reaction, such as ethers (e.g., diethyl ether, dioxane, tetrahydrofuran etc.), saturated hydrocarbons (e.g., hexane, pentane etc.), aromatic

hydrocarbons (e.g., benzene, toluene etc.), halogenated hydrocarbons (e.g., dichloromethane, chloroform etc.) and the like. Of these, ethers such as tetrahydrofuran and the like are preferable. The amount of the solvent to be used is particularly preferably 50 to 60 equivalents, per 1 equivalent of compound (III). The amount of the compound (IV) to be used is about 1 to 20 equivalents, generally not less than 2.5 equivalents, preferably 2.8 to 3.0 equivalents, per 1 equivalent of compound (III). The reaction temperature is from -20°C to 100°C, preferably 10 to 50°C, and the reaction time is generally 5 minutes to 48 hours, preferably 1 to 5 hours.

The compound (V) can be obtained easily from the resulting reaction mixture by converting M^2 to H by a conventional method. As a conventional method to convert M^2 to H, for example, hydrolysis, solvolysis and the like are used. The solvent to be used for hydrolysis and solvolysis is, for example, a protic solvent (e.g., water, lower alcohol such as methanol, ethanol, propanol, isopropanol, butanol and the like that dissociates and releases proton easily, or a mixture thereof). An acid may be present at this time. The acid includes, for example, inorganic acid such as hydrochloric acid, sulfuric acid and the like, and the like. Generally, compound (V) can be produced by adding a protolytic solvent to the reaction mixture. When a protolytic solvent is added to the reaction mixture, it is preferably added by small portions. The amount of the protolytic solvent to be added is not less than one equivalent (1 to 50 equivalents), preferably not less than 3 equivalents (3 to 10 equivalents), per 1 equivalent of compound (III). In this case, the reaction temperature is generally -20°C to 100°C, preferably 10°C to 50°C, and the reaction time is 5 minutes to 24 hours, preferably about 10 minutes to 1 hour.

When compound (V) thus obtained is in a free state, it may be converted to a salt by a conventional method. When the

The reaction between compound (VI) and hydroxylamine or a salt thereof is generally carried out in a solvent. Examples of the solvent include pyridine solvent, such as pyridine, picoline, lutidine and the like, preferably pyridine and the like. The amount of the solvent to be used is generally 0.1 to 50 equivalents, particularly 0.1 to 1 equivalent, per 1 equivalent of compound (VI). The amount of hydroxylamine or a salt thereof to be used is generally not less than 1 equivalent (1 to 10 equivalents), preferably 1.1 to 1.5 equivalents, per 1 equivalent of compound (VI). The reaction temperature is from 0°C to 100°C, preferably 20°C to 50°C, and the reaction time is generally 5 minutes to 48 hours, preferably 1 to 5 hours.

The resulting product is then isolated by a conventional method or the reaction mixture as it is subjected to dehydration, whereby the compound (I) can be produced.

The dehydration can be carried out by, for example, reacting a dehydrating agent with compound (I). Examples of the dehydrating agent include acetic anhydride, phosphorus oxide, phosphorus chloride, thionyl chloride, N,N-dicyclohexylcarbodiimide, N,N-carbonyldiimidazole and the like. Of these, acetic anhydride and the like are preferable. The amount of use of the dehydrating agent is generally 0.5 to 20 equivalents, preferably 1.0 to 2.0 equivalents, per 1 equivalent of compound (VI). This reaction is advantageously carried out in a solvent. Examples of the solvent include ethers such as diethyl ether, dioxane, tetrahydrofuran and the like, aromatic hydrocarbons such as benzene, toluene and the like, halogenated hydrocarbons such as dichloromethane, chloroform and the like, and the like. It is possible to use the same solvent as used in the reaction of compound (VI) and hydroxylamine or a salt thereof, such as pyridine solvent (e.g., pyridine, picoline, lutidine etc.). The reaction temperature is generally 0°C to 150°C, preferably 100°C to 130°C and the reaction time is generally 5 minutes to 48 hours, preferably 1

to 5 hours.

When compound (I) thus obtained is in a free state, it may be converted to a salt by a conventional method. When the compound is obtained as a salt, it may be converted to a free
5 compound or a different salt by a conventional method. When the compound has a protecting group, it may be deprotected by a conventional method to be mentioned below. The compound (I) thus obtained can be isolated and purified from a reaction mixture by a known method, such as redissolution, concentration,
10 solvent extraction, fractional distillation, crystallization, recrystallization, chromatography and the like. It is also possible to subject the reaction mixture to the next reaction without isolation.

In each of the above-mentioned steps, a protecting group
15 may be introduced, where necessary, into a starting material or the objective compounds (I), (II), (III), (IIIa), (IV), (V) and (VI) or deprotected before or after each reaction. The introduction and deprotection of protecting groups can be conducted by a known method. A protecting group can be
20 eliminated by a method known *per se* or a method analogous thereto. For example, a reaction with an acid, base, ultraviolet radiation, hydrazine, phenylhydrazine, sodium N-methyldithiocarbamate, tetrabutylammonium fluoride, palladium acetate and the like or reduction and the like are employed.
25 When, for example, compound (V) is protected with a trityl group, the trityl group can be removed by, for example, a treatment under acidic conditions (e.g., heating), or hydrogenolysis and the like. The acid to be used is, for example, organic acid such as formic acid, acetic acid and the
30 like, inorganic acid such as hydrochloric acid and the like, and the like. The reaction may be carried out in a solvent inert to the reaction, such as alcohols, ethers (e.g., tetrahydrofuran etc.) and the like. The reaction temperature is generally 0°C to 100°C and the reaction time is generally 5

minutes to 48 hours, preferably 2 to 6 hours.

According to the method of the present invention, for example, the following compound (V) can be produced industrially advantageously.

5 1-(1H-Imidazol-4-yl)-1-(6-methoxynaphthalen-2-yl)-2-methylpropanol, 6-(1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl)-N-methyl-2-naphthamide, N-ethyl-6-(1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl)-2-naphthamide, 6-(1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl)-N-isopropyl-2-naphthamide,
10 N-cyclopropyl-6-(1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl)-2-naphthamide, and their salts and the like.

The compound (V) has a superior effect as a pharmaceutical and shows a superior inhibitory activity particularly against steroid C_{17,20} lyase. The compound (V)
15 shows low toxicity and fewer side effects. Therefore, it is useful as an agent for the treatment and prevention of various diseases in mammals (e.g., humans, bovines, horses, dogs, cats, monkeys, mice, rats etc., particularly humans) such as (1) primary carcinoma of malignant tumor (e.g., prostate cancer,
20 breast cancer, uterine cancer, ovarian cancer etc.), and metastatic cancer and recurrent carcinoma thereof, (2) various symptoms associated with these cancers (e.g., pain, cachexia etc.), (3) prostatic hypertrophy, masculinism, hypertrichiasis, male-pattern baldness, male infantile precocity, endometriosis,
25 hystero myoma, adenomyosis of uterus, mastopathy, polycystic ovary syndrome and the like.

The compound (V) shows a superior effect even when used alone, and the effect can be reinforced even more when used together with other pharmaceutical preparation and therapeutic
30 method. Examples of the combination drug include, but not limited to, sex hormone agent, alkylating agent, antimetabolite, carcinostatic antibiotic, plant alkaloid, immunotherapeutic drug and the like.

As the therapy to be combined, there are mentioned, for

example, operation, thermotherapy, radiation therapy and the like. Together with chemotherapy including administration of the compound (V), for example, a therapeutic method other than chemotherapy, such as an operation inclusive of orchidectomy,
 5 thermotherapy, radiation therapy and the like, can be used in combination.

As a pharmacologically acceptable carrier, various organic or inorganic carrier substances in common use as pharmaceutical materials are used by adding them in a suitable
 10 amount as excipients, lubricants, binders, disintegrants and thickeners for solid preparations; solvents, dispersants, dissolution aids, suspending agents, isotonicity agents, buffers, soothing agent and the like for liquid preparations. Where necessary, additives such as antiseptics, antioxidants,
 15 coloring agents, sweetening agents and the like can be used according to a conventional method. Examples of preferable excipients include lactose, sucrose, D-mannitol, starch, crystalline cellulose, light silicic anhydride and the like. Examples of preferable lubricants include magnesium stearate,
 20 calcium stearate, talc, colloidal silica and the like. Examples of preferable binder include crystalline cellulose, sucrose, D-mannitol, dextrin, hydroxypropylcellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone and the like. Examples of preferable disintegrators include starch,
 25 carboxymethyl cellulose, carboxymethyl cellulose calcium, crosslinked carmellose sodium, carboxymethyl starch sodium and the like. Examples of preferable thickener include natural gums, cellulose derivative, polyacrylic acid and the like. Examples of preferable solvents include water for injection,
 30 alcohol, propylene glycol, Macrogol, sesame oil, corn oil and the like. Examples of preferable dispersant include Tween 80, HCO 60, polyethylene glycol, carboxymethyl cellulose, alginate sodium and the like. Examples of preferable dissolution aids include polyethylene glycol, propylene glycol, D-mannitol,

benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate and the like. Examples of preferable suspending agents include surfactant (e.g., stearyltriethanolamine, sodium lauryl sulfate, 5 laurylaminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, glycerine monostearate etc.), hydrophilic macro molecule (e.g., polyvinyl alcohol, polyvinyl pyrrolidone, carboxymethyl cellulose sodium, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, 10 hydroxypropylcellulose etc.) and the like. Examples of preferable isotonicity agents include sodium chloride, glycerine, D-mannitol and the like. Examples of preferable buffers include buffering solutions of phosphate, acetate, carbonate and citrate, and the like. Examples of preferable 15 soothing agents include benzyl alcohol and the like. Examples of preferable antiseptics include p-hydroxybenzoic esters, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid and the like. Examples of preferable antioxidants include sulfite, ascorbic acid and the like.

20 A pharmaceutical preparation containing compound (V) can be produced according to a conventional method. Specific examples are shown in the following.

(1) tablet, powder, granule, capsule:

Excipient, disintegrator, binder, lubricant or the like 25 is added to compound (V) and the mixture is compression formed. Where necessary, taste masking, enteric coating or a coating for sustained release is applied.

(2) injection:

The compound (V) is formulated together with, for 30 example, dispersant, preservative, isotonizing agent and the like to give an aqueous injection, or dissolved, suspended or emulsified in a vegetable oil such as olive oil, sesame oil, cottonseed oil, corn oil and the like, propylene glycol and the like and prepared to give an oily injection.

(3) suppository:

A suppository can be produced by making the compound (V) into an oily or aqueous solid, semisolid or liquid composition. Examples of the oily base to be used for such a composition include glyceride of higher fatty acid (e.g., cacao butter, Witepsol), medium fatty acid (e.g., migliols), vegetable oil (e.g., sesame oil, soybean oil, cottonseed oil etc.) and the like. Examples of the aqueous gel base that can be used for this composition include natural gums, cellulose derivative, vinyl polymer, acrylate polymer and the like.

While the proportion of compound (V) to be contained in these preparations varies depending on the kind of preparation, it is generally 0.01 to 50%.

While the amount of use of compound (V) in the aforementioned pharmaceutical preparation varies depending on the compound to be selected, animal species to be the administration target, administration frequency and the like, compound (V) shows effectiveness over a wide range of application. When, for example, a pharmaceutical preparation containing compound (V) is orally administered to an adult patient with a solid tumor (e.g., patient with prostate cancer), the daily dose in the effective amount of the compound (V) is generally about 0.001 to about 500 mg/kg body weight, preferably about 0.1 to about 40 mg/kg body weight, more preferably about 0.5 to about 20 mg/kg body weight. In the case of parenteral administration and concurrent use with other anticancer agent, the dose is smaller than these. However, the amount of compound (V) actually administered is determined depending on the kind of compound (V), mode of preparation, age, body weight and sex of patient, level of disease, administration route, period and intervals of the administration, and the like, and can be changed any time depending on the judgement of doctors.

The administration route of the aforementioned

pharmaceutical preparation is not particularly limited as long as the object can be achieved, but the preparation can be administered orally or parenterally. The term "parenteral" used herein includes intravenous, intramuscular, subcutaneous, 5 intranasal, intradermal, instillation, intracerebral, intrarectal, intravaginal and intraperitoneal administrations and the like.

The period and intervals of the administration of the aforementioned pharmaceutical preparation are modified 10 according to various conditions and determined according to the judgment of doctors at any time. The administration method includes, for example, divisional administration, consecutive daily administration, intermittent administration, administration in large amounts in a short period, repeat 15 administration and the like. In the case of oral administration, for example, the preparation is desirably administered once a day to several times a day (particularly 2 or 3 times a day) by dividing the dose. It is also possible to administer the preparation as a sustained release preparation 20 or an intravenous infusion to be administered over a long time.

Best Mode For Carrying Out The Invention

The present invention is explained in more detail by way of the following Examples. These Examples are mere embodiments and do not limit the present invention in any way. They can be 25 modified as long as they do not deviate from the scope of the present invention. In the Examples, the abbreviations mean the following.

s: singlet, d: doublet, t: triplet, q: quartet, dd: double doublet, dt: double triplet, m: multiplet, br: broad, J: 30 coupling constant, room temperature: 0 to 30°C, DMF: dimethylformamide, THF: tetrahydrofuran, IPE: isopropyl ether.

Example 1

Production of 1-(1H-imidazol-4-yl)-2-methyl-1-propanone

A solution of 4-cyanoimidazole (42.7 g, 0.458 mol) in THF (500 ml) was added dropwise over 30 min to a solution (1.4 L, 1.47 mol, 3.2 equivalents) of 1.1 M isopropyl magnesium bromide in THF at 0 to 10°C under a nitrogen atmosphere. The mixture was stirred at 15 to 25°C for 3 h. Water (430 ml) and 10% aqueous sulfuric acid solution (860 ml) were successively added dropwise, and the mixture was stirred at 30 min. A 30% aqueous sodium hydroxide solution was added dropwise to adjust the pH to 8. After partitioning, the aqueous layer was extracted with ethyl acetate (300 ml x 2). The organic layer was combined, and the mixture was washed successively with saturated aqueous sodium hydrogencarbonate and saturated brine, and concentrated under reduced pressure. The concentration residue was broken up with isopropyl ether (300 ml). The crystals were collected by filtration and washed with isopropyl ether. The crystals were dried in vacuo (40°C) to give 1-(1H-imidazol-4-yl)-2-methyl-1-propanone (51.9 g, yield 82%).

¹H-NMR (CDCl₃): δ 1.25(6H, d, J=6.9Hz), 3.36(1H, quint, J=6.9Hz), 7.81(1H, s), 7.87(1H, s)

Example 2

Production of 1-(1H-imidazol-4-yl)-1-(6-methoxynaphthalen-2-yl)-2-methylpropanol

THF (14 ml) was added to magnesium (0.55 g, 22.4 mmol) under a nitrogen atmosphere. Iodine (3 mg) was added and the mixture was stirred. While keeping the mixture at not higher than 50°C, a solution of 2-bromo-6-methoxynaphthalene (5.15 g, 21.7 mmol.) in THF (12 ml) was added dropwise, and the mixture was stirred at 15 to 25°C for 1.5 h. A solution of 1-(1H-imidazol-4-yl)-2-methyl-1-propanone (1 g, 7.24 mmol) in THF (5 ml) was added dropwise at -20°C, and the mixture was stirred at 15 to 25°C for 8 h. A saturated aqueous sodium hydrogencarbonate (5 ml) and water (5 ml) were successively added dropwise. After stirring, the mixture was passed through celite. After partitioning, the aqueous layer was extracted

with ethyl acetate (5 ml). The organic layer was combined, and the mixture was washed with saturated brine and concentrated under reduced pressure. The concentration residue was broken up with ethyl acetate (6 ml) and isopropyl ether (12 ml), and
 5 the crystals were collected by filtration and washed with isopropyl ether (12 ml). The crystals were dried in vacuo (40°C) to give 1-(1H-imidazol-4-yl)-1-(6-methoxynaphthalen-2-yl)-2-methylpropanol (1.8 g, yield 84%).

Example 3

10 Production of 1-(1H-imidazol-4-yl)-1-propanone

A solution of 4-cyanoimidazole (2 g, 21.4 mmol) in THF (25 ml) was added dropwise to a solution (68.5 mL, 68.5 mmol, 3.2 equivalents) of 1 M ethyl magnesium bromide in THF at 0 to 10°C under a nitrogen atmosphere. The mixture was stirred at
 15 15 to 25°C for 4 h. Water (20 ml) and 10% aqueous sulfuric acid solution (45 ml) were successively added dropwise, and the mixture was stirred for 1 h. A 30% aqueous sodium hydroxide solution was added dropwise to adjust the pH to 8. After partitioning, the aqueous layer was extracted with ethyl
 20 acetate (15 ml x 2). The organic layer was combined, and the mixture was washed successively with saturated aqueous sodium hydrogencarbonate and saturated brine, and concentrated under reduced pressure. The concentration residue was broken up with n-hexane (6 ml), and the crystals were collected by filtration
 25 and washed with n-hexane. The crystals were dried in vacuo (40°C) to give 1-(1H-imidazol-4-yl)-1-propanone (1.68 g, yield 63%).

¹H-NMR (CDCl₃): δ1.06(3H, t, J = 7.4 Hz), 2.86(2H, q, J = 7.4 Hz), 7.81(1H, s), 7.84(1H, s)

30 Example 4

Production of 1-(1H-imidazol-4-yl)-1-butanone

A solution of 4-cyanoimidazole (2 g, 21.4 mmol) in THF (25 ml) was added dropwise to a solution (68.5 mL, 68.5 mmol, 3.2 equivalents) of 1 M n-propyl magnesium bromide in THF at 0

to 10°C under a nitrogen atmosphere. The mixture was stirred at 15 to 25°C for 4 h. Water (20 ml) and 10% aqueous sulfuric acid solution (45 ml) were successively added dropwise, and the mixture was stirred at 1 h. A 30% aqueous sodium hydroxide solution was added dropwise to adjust the pH to 8. After partitioning, the aqueous layer was extracted with ethyl acetate (15 ml x 2). The organic layer was combined, and the mixture was washed successively with saturated aqueous sodium hydrogencarbonate and saturated brine, and concentrated under reduced pressure. The concentration residue was broken up with n-hexane (12 ml), and the crystals were collected by filtration and washed with n-hexane. The crystals were dried in vacuo (40°C) to give 1-(1H-imidazol-4-yl)-1-butanone (2.45 g, yield 83%).

¹H-NMR (CDCl₃): δ0.90(3H, t, J=7.4Hz), 1.60(2H, q, J=7.3Hz), 3.34(2H, q, J=7.1Hz), 7.77(1H, s), 7.85(1H, s)

Example 5

Production of 4-cyanoimidazole

Pyridine (150 ml) was added to 4-formylimidazole (50 g, 0.52 mol), and hydroxylamine hydrochloride (40.5 g, 0.585 mol, 1.13 equivalents) was added while stirring the mixture. After stirring for 2 h, acetic anhydride (92.3 ml, 0.978 mol) was added dropwise. The mixture was stirred as it was until the temperature reached room temperature, and 30% aqueous sodium hydroxide solution was added dropwise in a water bath to adjust the pH to 7.9. Ethyl acetate (380 ml) was added for extraction, and the aqueous layer was extracted again with ethyl acetate (250 ml). The organic layer was combined, washed twice with saturated brine and concentrated under reduced pressure. Toluene was added to the concentration residue and the mixture was concentrated under reduced pressure (twice). The concentration residue was broken up with IPE (100 ml), and the crystals were collected by filtration and washed with IPE. The crystals were dried in vacuo (40°C) to give 4-cyanoimidazole

(42.7 g, yield 88.0%).

¹H-NMR (DMSO-d₆): δ7.91(1H, s), 8.10(1H, s)

Industrial applicability

According to the present invention, a compound having a
5 steroid C_{17,20} lyase inhibitory action can be produced
industrially advantageously in a high yield with a less number
of steps without using a heavy metal compound.

[illegible]

10



10




15 wherein M^1 is an alkali metal atom or a group of the formula:
-Mg-Y¹ (Y¹ is a halogen atom) and R is as defined above, or a
salt thereof, and bringing the resulting product into contact
with an acid.

20




optionally substituted heterocyclic group, ring A is an

imidazole ring which is optionally substituted further, and R^1 , R^2 , R^3 , R^4 , R^5 , R^6 and R^7 are each independently a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted hydroxyl group, an optionally substituted thiol group, an optionally substituted amino group, an acyl group or a halogen atom, or a salt thereof, which method comprises reacting a compound of the formula:




wherein each symbol is as defined above, or a salt thereof, and
10 a compound of the formula:



wherein M^2 is an alkali metal atom or a group of the formula:
-Mg-Y² (Y² is a halogen atom) and other symbols are as defined
15 above, or a salt thereof.

(3) A method for producing a compound of the formula:



20 wherein R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, ring A is an imidazole ring which is optionally substituted further and R^1 ,


R^2 , R^3 , R^4 , R^5 , R^6 and R^7 are each independently a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted hydroxyl group, an optionally substituted thiol group, an optionally substituted amino group, an acyl group or
 5 a halogen atom, or a salt thereof, which method comprises reacting a compound of the formula:




wherein ring A is as defined above, or a salt thereof, and a compound of the formula:



wherein M^1 is an alkali metal atom or a group of the formula: $-Mg-Y^1$ (Y^1 is a halogen atom) and R is as defined above, or a salt thereof, and bringing the resulting product into contact with an acid to give a compound of the formula:




15 wherein each symbol is as defined above, or a salt thereof, and then reacting this compound and a compound of the formula:



20 wherein M^2 is an alkali metal atom or a group of the formula: $-Mg-Y^2$ (Y^2 is a halogen atom) and other symbols are as defined above, or a salt thereof.


(4) A method for producing a compound of the formula:



wherein R is an optionally substituted hydrocarbon group or an
 5 optionally substituted heterocyclic group, ring A is an
 imidazole ring which is optionally substituted further and R¹,
 R², R³, R⁴, R⁵, R⁶ and R⁷ are each independently a hydrogen atom,
 an optionally substituted hydrocarbon group, an optionally
 substituted hydroxyl group, an optionally substituted thiol
 10 group, an optionally substituted amino group, an acyl group or
 a halogen atom, or a salt thereof, which method comprises
 reacting a compound of the formula:



15 wherein ring A is as defined above, or a salt thereof and
 hydroxylamine or a salt thereof, subjecting the resulting
 product to dehydration to give a compound of the formula:



wherein ring A is as defined above, or a salt thereof, reacting
 20 this compound and a compound of the formula:




wherein M¹ is an alkali metal atom or a group of the formula:
 -Mg-Y¹ (Y¹ is a halogen atom) and R is as defined above, or a
 salt thereof, bringing the resulting product into contact with

an acid to give a compound of the formula:



wherein each symbol is as defined above, or a salt thereof, and then reacting this compound and a compound of the formula:



5

wherein M^2 is an alkali metal atom or a group of the formula: $-Mg-Y^2$ (Y^2 is a halogen atom) and other symbols are as defined above, or a salt thereof.

10 (5) The production method described in claim (1), (2), (3) or (4), wherein the ring A of the compounds of the formulas (I), (III), (V) and (VI) is an imidazole ring wherein the 1- or 3-position is optionally protected.

15 (6) The production method described in claim (1), (2), (3) or (4), wherein R is an optionally substituted lower alkyl group, an optionally substituted lower alkenyl group, an optionally substituted cycloalkyl group, an optionally substituted phenyl group or an optionally substituted pyridyl group.

20

(7) The production method described in claim (1), (2), (3) or (4), wherein R is a lower alkenyl group, a cycloalkyl group, a phenyl group, a pyridyl group, or a lower alkyl group optionally substituted by a halogen atom.

25

(8) The production method described in claim (1), (2), (3) or

(9) The production method described in claim (1), (2), (3) or (4), wherein R is an isopropyl group.

(10) The production method described in claim (2), (3) or (4), wherein M^2 is sodium, potassium or a group of the formula: $-Mq-Y^2$ (Y^2 is a halogen atom).


10 (11) The production method described in claim (1), (3) or (4), wherein the reaction product of a compound of the formula (I) or a salt thereof and a compound of the formula (II) or a salt thereof is brought into contact with a sulfuric acid.

15 (12) The production method described in claim (1), (3) or (4), wherein not less than 3 equivalents of the compound of the formula (II) or a salt thereof is used per one equivalent of the compound of the formula (I) or a salt thereof.

20 (13) The production method described in claim (1), (3) or (4), wherein the compound of the formula (I) or a salt thereof and the compound of the formula (II) or a salt thereof are reacted in tetrahydrofuran.

25 (14) The production method described in claim (1), (3) or (4), wherein the compound of the formula (I) or a salt thereof and the compound of the formula (II) or a salt thereof are reacted in not less than 50 equivalents of a solvent relative to one equivalent of the compound of the formula (I) or a salt thereof.

(15) A compound of the formula:



(IIIa)

wherein R' is an optionally substituted alkyl group having 3 or more carbon atoms, or a salt thereof.


5 (16) The compound of claim (15), wherein R' is an optionally substituted branched alkyl group having 3 or more carbon atoms.

(17) 1-(1H-Imidazol-4-yl)-2-methyl-1-propanone or a salt thereof.

10

Abstract

The present invention provides an industrially advantageous production method of compound (V) having a steroid C_{17,20} lyase inhibitory action, which affords this compound in a high yield with a less number of steps without using a heavy metal compound:



wherein ring A is an optionally substituted imidazole ring, R is an optionally substituted hydrocarbon group or a heterocyclic group, and R¹, R², R³, R⁴, R⁵, R⁶ and R⁷ are each a hydrogen atom, an optionally substituted hydrocarbon group, OH, SH or NH₂, an acyl group or a halogen and the like.



RECEIVED

APR 17 2002

TECH CENTER 1600/2900

PTO/SB/106 (5-00)

Approved for use through 10/31/02. OMB 0651-0032
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Declaration and Power of Attorney for Patent Application

特許出願宣言書及び委任状

Japanese Language Declaration

日本語宣言書

私は、以下に記名された発明者として、ここに下記の通り宣言する：

As a below named inventor, I hereby declare that:

私の住所、郵便の宛先そして国籍は、私の氏名の後に記載された通りである。

My residence, post office address and citizenship are as stated next to my name.

下記の名称の発明について、特許請求範囲に記載され、且つ特許が求められている発明主題に関して、私は、最初、最先且つ唯一の発明者である（唯一の氏名が記載されている場合）か、或いは最初、最先且つ共同発明者である（複数の氏名が記載されている場合）と信じている。

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

PRODUCTION METHOD OF IMIDAZOLE DERIVATIVES

上記発明の明細書はここに添付されているが、下記の欄がチェックされている場合は、この限りでない：

the specification of which is attached hereto unless the following box is checked.

☐ _____ の日に出願され、
この出願の米国出願番号または PCT 国際出願番号は、
_____ であり、且つ
_____ の日に補正された出願（該当する場合）

☒ was filed on June 21, 2000
as United States Application Number or
PCT International Application Number
PCT/JP00/04036 and was amended on
_____ (if applicable)

私は、上記の補正書によって補正された、特許請求範囲を含む上記明細書を検討し、且つ内容を理解していることをここに表明する。

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

私は、連邦規則法典第 37 編規則 1.56 に定義されている、特許性について重要な情報を開示する義務があることを認める。

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the need of the individual case. Any comments on the amount of time you are required to complete this form should be sent to Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents and Trademarks, Washington, DC 20231.

Japanese Language Declaration (日本語宣言書)

私は、ここに、以下に記載した外国での特許出願または発明者証の出願、或いは米国以外の少なくとも一国を指定している米国法典第35編第365条(a)によるPCT国際出願について、同第119条(a)-(d)項又は第365条(b)項に基づいて優先権を主張するとともに、優先権を主張する本出願の出願日より前の出願日を有する外国での特許出願または発明者証の出願、或いはPCT国際出願については、いかなる出願も、下記の枠内をチェックすることにより示した。

I hereby claim foreign priority under Title 35, United States Code, Section 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT International application which designated at least one country other than the United States listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application for which priority is claimed

Prior Foreign Application(s)
外国での先行出願

Priority Claimed
優先権主張

175070/1999	Japan
(Number) (番号)	(Country) (国名)
(Number) (番号)	(Country) (国名)

22/06/1999
(Day/Month/Year Filed) (出願日/月/年)
(Day/Month/Year Filed) (出願日/月/年)

<input checked="" type="checkbox"/>	<input type="checkbox"/>
Yes はい	No いいえ
<input type="checkbox"/>	<input type="checkbox"/>
Yes はい	No いいえ

私は、ここに、下記のいかなる米国仮特許出願についても、その米国法典第35編第119条(e)項の利益を主張する。

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

(Application No.) (出願番号)	(Filing Date) (出願日)
-----------------------------	------------------------

(Application No.) (出願番号)	(Filing Date) (出願日)
-----------------------------	------------------------

私は、ここに、下記のいかなる米国出願についても、その米国法典第35編第120条に基づく利益を主張し、又米国を指定するいかなるPCT国際出願についても、その同第365条(c)に基づく利益を主張する。また、本出願の各特許請求の範囲の主題が、米国法典第35編第112条第1段に規定された態様で、先行する米国出願又はPCT国際出願に開示されていない場合においては、その先行出願の出願日と本国内出願日またはPCT国際出願日との間の期間中に入手された情報で、連邦規則法典第37編規則1.56に定義された特許性に関わる重要な情報について開示義務があることを承認する。

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s), or 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of application.

PCT/JP00/04036	21/06/2000
(Application No.) (出願番号)	(Filing Date) (出願日)

Pending
(Status: Patented, Pending, Abandoned) (現況: 特許許可、係属中、放棄)

(Application No.) (出願番号)	(Filing Date) (出願日)
-----------------------------	------------------------

(Status: Patented, Pending, Abandoned) (現況: 特許許可、係属中、放棄)

私は、ここに表明された私自身の知識に係わる陳述が真実であり、且つ情報と信ずることに基づく陳述が、真実であると信じられることを宣言し、さらに、故意に虚偽の陳述などを行った場合は、米国法典第18編第1001条に基づき、罰金または拘禁、若しくはその両方により処罰され、またそのような故意による虚偽の陳述は、本出願またはそれに対して発行されるいかなる特許も、その有効性に問題が生ずることを理解した上で陳述が行われたことを、ここに宣言する。

I hereby declare that all statements made herein of my own knowledge and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Japanese Language Declaration (日本語宣言書)

委任状： 私は本出願を審査する手続を行い、且つ米国特許商標庁との全ての業務を遂行するために、記名された発明者として、下記の弁護士及び/または弁理士を任命する。(氏名及び登録番号を記載すること)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith (list name and registration number)

Mark Chao, Reg. No. 37293; Elaine M. Ramesh, Reg. No. 43032

書類送付先

Send Correspondence to:

Mark Chao, PhD, JD.

Intellectual Property Department

Takeda Pharmaceuticals North America, Inc.

Suite 500, 475 Half Day Road

Lincolnshire, IL 60069 USA

直通電話連絡先：(氏名及び電話番号)

Direct Telephone Calls to: (name and telephone number)

Mark Chao, PhD JD

Voice: (847)383-3391 Fax: (847)383-3481

Elaine M. Ramesh, PhD JD

Voice: (847)383-3391 Fax: (847)383-3481

唯一または第一発明者氏名

Full name of sole or first inventor

1-00 Jun-ichi KAWAKAMI

発明者の署名

日付

Inventor's signature

Date

Junichi Kawakami January 17, 2002

住所

Residence 4-6-301, Kitashinmachi, Ikoma-shi, Nara

630-0245 JAPAN

国籍

Citizenship

Japan

郵便の宛先

Post Office Address

same as above

第二共同発明者がいる場合、その氏名

Full name of second joint inventor, if any

第二共同発明者の署名

日付

Second inventor's signature

Date

住所

Residence

国籍

Citizenship

Japan

郵便の宛先

Post Office Address

(第三以下の共同発明者についても同様に記載し、署名をすること)

(Supply similar information and signature for third and subsequent joint inventors.)